Association between platelet distribution width and prognosis in patients with heart failure

Yu Sato, Akiomi Yoshihisa, Koichiro Watanabe, Yu Hotsuki, Yusuke Kimishima, Tetsuro Yokokawa, Tomofumi Misaka, Takamasa Sato, Takashi Kaneshiro, Masayoshi Oikawa, Atsushi Kobayashi, Yasuchika Takeishi

1 Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan, 2 Department of Advanced Cardiac Therapeutics, Fukushima Medical University, Fukushima, Japan

*yoshihis@fmu.ac.jp

Abstract

Background
The prognostic impact of platelet distribution width (PDW), which is a specific marker of platelet activation, has been unclear in patients with heart failure (HF).

Methods and results
We conducted a prospective observational study enrolling 1,746 hospitalized patients with HF. Patients were divided into tertiles based on levels of PDW: 1\(^{st}\) (PDW < 15.9 fL, n = 586), 2\(^{nd}\) (PDW 15.9–16.8 fL, n = 617), and 3\(^{rd}\) (PDW ≥ 16.9, n = 543) tertiles. We compared baseline patients' characteristics and post-discharge prognosis: all-cause death; cardiac death; and cardiac events. The 3\(^{rd}\) tertile showed the highest age and levels of B-type natriuretic peptide compared to other tertiles (1\(^{st}\), 2\(^{nd}\), and 3\(^{rd}\) tertiles; age, 69.0, 68.0, and 70.0 years old, P = 0.038; B-type natriuretic peptide, 235.2, 171.9, and 241.0 pg/mL, P < 0.001). Left ventricular ejection fraction was equivalent among the tertiles. In the Kaplan-Meier analysis, rates of all endpoints were the highest in the 3\(^{rd}\) tertile (log-rank P < 0.001, respectively). The Cox proportional hazard analysis revealed that the 3\(^{rd}\) tertile was associated with adverse prognosis (all-cause death, hazard ratio [HR] 1.716, P < 0.001; cardiac death, HR 1.919, P < 0.001; cardiac event, HR 1.401, P = 0.002).

Conclusions
High PDW is a novel predictor of adverse prognosis in patients with HF.

Introduction
Accurate risk stratification and estimation of prognosis are critically important in patients with heart failure (HF) [1, 2]. Current major guidelines recommend laboratory evaluation, including complete blood count [1, 2]. However, the usefulness of complete blood count other
than hemoglobin or hematocrit in predicting prognosis has yet to be fully evaluated [1–3]. Red blood cell distribution width has been attracting great interest in recent years as a novel prognostic marker in patients with cardiovascular disease [4, 5]. Felker et al. firstly reported that higher red blood cell distribution width was independently and strongly associated with all-cause death in patients with HF [4]. Subsequently, Tonelli et al. analyzed data from a large cohort of patients with myocardial infarction, and found that red blood cell distribution width was also useful in predicting all-cause death [5]. Complete blood count routinely reports not only red blood cell distribution width, but also platelet distribution width (PDW). PDW is defined as the distribution width (femtoliter, fL) at 20% of the total height of the platelet size distribution curve, measures the variability in platelet size, and is a marker of platelet activation [6–8]. Increased levels of PDW are presumed to be associated with atherosclerosis, coronary artery disease (CAD), cerebrovascular disease, and systemic inflammatory disease [9–11]. These diseases play key roles in the pathophysiology of HF [1, 2, 12–14]. Moreover, levels of PDW predicts the occurrence of cardiac death, infarction recurrence, and another revascularization in patients with acute myocardial infarction [7, 15]. In addition to routine clinical laboratory tests, new biomarkers reflecting various pathophysiological aspects can be useful adjuncts for the diagnosis, prognosis prediction, and treatment of HF [1, 2]. Thus, the aim of the present study was to evaluate PDW as a prognostic marker in patients with HF.

Methods

This was a prospective and observational study. The patient flowchart is shown in Fig 1. The inclusion criteria included patients who 1) were both hospitalized for acute decompensated HF at, and discharged from, Fukushima Medical University Hospital between October 2009 and September 2019; and (2) were measured for PDW. HF was diagnosed in accordance with the current guidelines [1, 2, 16]. A total of 2,450 patients met the criteria. Among them, patients who were receiving maintenance dialysis and/or those with a history of cancer, including blood cancer, were excluded (n = 704). The definition of cancer was in accordance with our previous study [17]. Finally, a total of 1,746 patients were enrolled. We divided these patients into tertiles according to PDW level: patients with PDW in the lowest tertile (1st tertile, PDW < 15.9 fL, n = 586, 33.6%); those with PDW in the middle tertile (2nd tertile, PDW 15.9–16.8 fL, n = 617, 35.3%); and those with PDW in the highest tertile (3rd tertile, PDW ≥ 16.9 fL, n = 543, 31.1%). We compared baseline characteristics and post-discharge prognosis. The baseline characteristics comprised demographic data at discharge.
comorbidities, medications at discharge, and laboratory and echocardiographic data obtained within 1 week prior to discharge in a stable condition. Comorbidities were defined in accordance with our previous studies [17, 18]. Anemia was defined as levels of hemoglobin of less than 13 g/dL in men and less than 12 g/dL in women [19]. CAD was defined by the following: medical history, myocardial scintigraphy, coronary CT angiography, and/or coronary angiography [18]. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min/1.73 m$^2$ using a three-variable Japanese equation [20, 21]. The primary endpoints were all-cause death, cardiac death, and cardiac event. A cardiac death was defined as a death from worsened HF, ventricular fibrillation, or acute coronary syndrome. A cardiac event was defined as a cardiac death or an unplanned hospitalization for HF. If two or more cardiac events occurred in one patient, the first event was used for analyses as a cardiac event. This study complied with the Declaration of Helsinki and the statement of STROBE (Strengthening the Reporting of Observational studies in Epidemiology) [22, 23]. The study protocol was approved by the ethical committee of Fukushima Medical University. All patients gave written informed consent to participate in this study.

PDW was analyzed from anticoagulated blood (ethylenediaminetetraacetic acid bulb) using an automated hematology analyzer, UniCel DxH 800 (BECKMAN COULTER, Brea, CA, USA) within 1 week prior to discharge in a stable condition. This procedure was performed by experienced laboratory technicians at Fukushima Medical University Hospital who were independent of this study.

Continuous variables were expressed as a median (25$^{th}$, 75$^{th}$ percentile) because the Shapiro-Wilk test revealed that all the continuous variables analyzed in this study were non-normally distributed. Categorical variables were presented as counts (percent). Continuous variables were compared using the Kruskal-Wallis test followed by the Steel-Dwass post-hoc test. Categorical variables were compared using the chi-square test. The Kaplan-Meier analysis with log-rank test was used for presenting the primary endpoints. We assessed PDW as a predictor of the primary endpoints using the Cox proportional hazard analysis. Hazard ratio (HR) and 95% confidence interval (CI) were further adjusted for age, sex, and variables that were significantly different among the groups. The threshold for statistical significance was $P < 0.05$ for all the analyses. The Kruskal-Wallis test and the Steel-Dwass post-hoc test were performed using EZR version 1.40 (Saitama Medical Center, Jichi Medical University, Saitama, Japan) [24]. All other analyses were conducted using IBM SPSS Statistics version 26 (IBM, Armonk, NY, USA).

**Results**

The distribution of patients according to PDW level is shown in Fig 2, and comparisons of the baseline patient characteristics are summarized in Table 1. The PDW levels in the 1$^{st}$, 2$^{nd}$, and 3$^{rd}$ tertiles were 13.4 (12.2, 14.2), 16.5 (16.2, 16.7), and 17.3 (17.0, 17.7) fL, respectively ($P < 0.001$). There were U-shaped associations between PDW tertiles and several important factors such as age, hypertension, diabetes mellitus, coronary artery disease, and levels of B-type natriuretic peptide. On the other hand, the prevalence of chronic kidney disease was highest in the 3$^{rd}$ tertile, followed by the 2$^{nd}$, then 1$^{st}$ tertiles (57.5%, 49.3%, and 49.0% respectively, $P = 0.005$). Left ventricular ejection fraction was equivalent among the groups ($P = 0.786$).

During the post-discharge follow-up period (median 1,352 days), there were 391 all-cause deaths including 212 cardiac deaths, and 480 cardiac events including 399 unplanned hospitalizations for HF and 81 cardiac deaths. The Kaplan-Meier analysis demonstrated that the rates of all the primary endpoints were highest in the 3$^{rd}$ tertile (Fig 3, log-rank $P < 0.001$, respectively). Table 2 summarizes the results of the Cox proportional hazard analysis. In the
Table 1. Baseline patient characteristics (n = 1,746).

|                | 1<sup>st</sup> tertile (n = 586) | 2<sup>nd</sup> tertile (n = 617) | 3<sup>rd</sup> tertile (n = 543) | P value |
|----------------|----------------------------------|----------------------------------|----------------------------------|---------|
| **PDW, fL**    | 13.4 (12.2, 14.2)                | 16.5 (16.2, 16.7)                | 17.3 (17.0, 17.7)                | < 0.001 |
| **Demographic data** |                                  |                                  |                                  |         |
| Age, years old | 69.0 (58.0, 77.0)                | 68.0 (56.0, 77.0)                | 70.0 (59.0, 78.0)                | 0.038   |
| Male sex, n (%)| 353 (60.2)                       | 358 (58.0)                       | 330 (60.8)                       | 0.592   |
| Body mass index, kg/m<sup>2</sup> | 23.2 (21.0, 26.2)               | 22.9 (20.6, 25.5)                | 22.8 (20.6, 25.9)                | 0.273   |
| Smoking history, n, (%) | 301 (52.4)                      | 300 (49.5)                       | 294 (54.4)                       | 0.241   |
| **Comorbidity** |                                  |                                  |                                  |         |
| Hypertension, n (%) | 451 (77.0)                     | 372 (60.3)                       | 346 (63.7)                       | < 0.001 |
| Diabetes mellitus, n (%) | 236 (40.3)                     | 188 (30.5)                       | 232 (42.7)                       | < 0.001 |
| Dyslipidemia, n (%) | 451 (77.0)                     | 390 (63.2)                       | 378 (69.6)                       | < 0.001 |
| Hyperuricemia, n (%) | 341 (58.2)                     | 335 (54.3)                       | 339 (62.4)                       | 0.020   |
| Anemia, n (%)    | 283 (48.3)                      | 254 (41.2)                       | 285 (52.5)                       | < 0.001 |
| Atrial fibrillation, n (%) | 206 (35.2)                  | 236 (38.2)                       | 218 (40.1)                       | 0.215   |
| CAD, n (%)       | 225 (38.4)                      | 159 (25.8)                       | 166 (30.6)                       | < 0.001 |
| CVA, n (%)       | 105 (17.9)                      | 93 (15.1)                        | 93 (17.1)                        | 0.392   |
| PAD, n (%)       | 65 (18.3)                       | 56 (15.1)                        | 51 (16.3)                        | 0.512   |
| CKD, n (%)       | 287 (49.0)                      | 304 (49.3)                       | 312 (57.5)                       | 0.005   |
| COPD, n (%)      | 129 (28.2)                      | 153 (27.8)                       | 140 (30.4)                       | 0.643   |
| **Medication**   |                                  |                                  |                                  |         |
| RAS inhibitors, n (%) | 450 (76.8)                   | 419 (67.9)                       | 376 (69.2)                       | 0.001   |
| Beta blockers, n (%) | 435 (74.2)                   | 439 (71.2)                       | 379 (69.8)                       | 0.233   |
| Loop diuretics, n (%) | 393 (67.1)                    | 398 (64.5)                       | 380 (70.0)                       | 0.141   |
| Anticoagulants, n (%) | 321 (54.8)                    | 376 (60.9)                       | 311 (57.3)                       | 0.093   |
| Antiplatelet agents, n (%) | 329 (56.1)                   | 301 (48.8)                       | 274 (50.5)                       | 0.029   |
| **BNP (pg/mL)** | 235.2 (64.8, 602.0)            | 171.9 (66.9, 458.9)              | 241.0 (92.0, 568.3)              | < 0.001 |
| **LVEF (%)**     | 53.0 (39.0, 63.3)              | 55.5 (39.0, 64.2)                | 54.7 (39.1, 64.4)                | 0.786   |

PDW, platelet distribution width; CAD, coronary artery disease; CVA, cerebrovascular accident; PAD, peripheral artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; RAS, renin-angiotensin system; BNP, B-type natriuretic peptide; LVEF, left ventricular ejection fraction.

*P < 0.05 vs. 1<sup>st</sup> tertile and †P < 0.05 vs. 2<sup>nd</sup> tertile.
unadjusted analysis, the 3rd tertile (vs. 2nd and 1st tertiles) were associated with all primary end-points. In the multivariate analysis, the 3rd tertile was independently associated with adverse prognosis compared to the 2nd and 1st tertiles.

Considering the results from multivariate Cox proportional hazard analysis, we performed the logistic regression analysis to determine the factors associated with high (3rd tertile) PDW (S1 Table). Age, sex and factors which differed significantly in Table 1 were evaluated. From

Table 2. Cox proportional hazard analysis: The prognostic impact of PDW.

|                        | Unadjusted                  | Adjusted *                  |
|------------------------|-----------------------------|-----------------------------|
|                        | HR (95% CI)                 | P value                     | HR (95% CI)                 | P value |
| **All-cause death**    |                             |                             |                             |         |
| (event n = 391/1,746)  |                             |                             |                             |         |
| 2nd tertile (vs. 1st tertile) | 1.012 (0.779–1.314)  | 0.930                       | –                           | –       |
| 3rd tertile (vs. 1st tertile) | 1.716 (1.356–2.172)  | < 0.001                     | 1.301 (1.003–1.688)   | 0.047   |
| 3rd tertile (vs. 2nd tertile) | 1.696 (1.310–2.196)  | < 0.001                     | 1.260 (0.959–1.656)   | 0.097   |
| **Cardiac death**      |                             |                             |                             |         |
| (event n = 212/1,746)  |                             |                             |                             |         |
| 2nd tertile (vs. 1st tertile) | 0.924 (0.640–1.334)  | 0.672                       | –                           | –       |
| 3rd tertile (vs. 1st tertile) | 1.919 (1.400–2.630)  | < 0.001                     | 1.421 (1.006–2.008)   | 0.046   |
| 3rd tertile (vs. 2nd tertile) | 2.077 (1.459–2.957) | < 0.001                     | 1.537 (1.059–2.232)   | 0.024   |
| **Cardiac event**      |                             |                             |                             |         |
| (event n = 480/1,746)  |                             |                             |                             |         |
| 2nd tertile (vs. 1st tertile) | 0.831 (0.659–1.048)  | 0.117                       | –                           | –       |
| 3rd tertile (vs. 1st tertile) | 1.401 (1.133–1.732)  | 0.002                       | 1.168 (0.926–1.472)   | 0.189   |
| 3rd tertile (vs. 2nd tertile) | 1.686 (1.339–2.123)  | < 0.001                     | 1.296 (1.021–1.645)   | 0.033   |

HR, hazard ratio; CI, confidence interval; PDW, platelet distribution width.

*Adjusted for age, sex, presence or absence of hypertension, diabetes mellitus, dyslipidemia, hyperuricemia, anemia, coronary artery disease, and chronic kidney disease, use of renin-angiotensin system inhibitors and antiplatelet agents, and log-transformed B-type natriuretic peptide.

https://doi.org/10.1371/journal.pone.0244608.t002
the multivariate model, diabetes mellitus and anemia were independently associated with high PDW with adjusted odds ratios of 1.352 and 1.275, respectively (S1 Table).

Discussion

To the best of our knowledge, the current study is the first to report that high PDW is an independent predictor of adverse prognosis in patients with HF. PDW tertiles showed U- or J-shaped associations with HF severity and prognosis, which suggests that there may be a threshold in PDW level for identifying patients who are at high risk of HF. These findings are pivotal for clinical practice because complete blood count is performed in almost all patients with HF, and PDW is reported routinely and automatically.

PDW and mean platelet volume are positively correlated, and both are simple parameters of platelet activation [25, 26]. PDW is a more specific marker of platelet activation than mean platelet volume, since it does not increase during simple platelet swelling [7, 27]. Growth factors and cytokines in the atherosclerotic processes may elevate levels of PDW through interference with platelet production in the bone marrow [28, 29]. Larger platelets are metabolically and enzymatically more active than smaller platelets [30]. Activated platelets stimulate thrombus formation, promoting atherothrombotic disease in response to rupture of an atherosclerotic plaque or endothelial cell erosion [31]. However, the clinical association between levels of PDW and CAD has been controversial. Higher PDW was previously reported to be independently associated with a high SYNTAX score, chronic total occlusion, inadequate coronary collateral, and in-stent restenosis in patients with CAD [8, 26, 29, 32]. On the other hand, De Luca et al. reported that PDW was not associated with CAD prevalence [33]. In terms of prognosis, higher levels of PDW have been reported to independently predict cardiac death and adverse cardiovascular events in patients with CAD [7, 34]. One plausible explanation for the discrepancy is the presence of the threshold shown in our results, which were consistent with those of a previous report [35].

According to He et al., who analyzed big data on retired employees, there were non-linear associations between levels of PDW and prognosis in terms of cardiovascular disease, CAD, and stroke [36]. In their report, participants with the lowest quintile had better prognosis compared to those with PDW in the 20–80th percentiles [36]. Considering the non-linear associations, PDW should be handled as a categorical variable divided by certain thresholds for prognosis prediction. In addition, there were significant differences regarding participant characteristics between our study and the above-mentioned studies, which suggests that the prognostic impact of PDW may differ according to the target population (e.g. patients with HF, those with CAD, or general population).

Although there have been numerous biomarkers reported in patients with HF, accurate risk stratification remains challenging [1, 2]. Natriuretic peptide (NP) is widely used to support diagnosis, prognostication, and management of patients with HF, but NPs come with limitations, including vulnerability to the presence of obesity, atrial fibrillation, and renal dysfunction, for example [37]. Aside from NPs, novel biomarkers may improve the understanding of the complex disease process of HF, and possibly personalize care for those affected through better individual phenotyping or understanding pathophysiologic pathways (e.g. myocardial stretch/stress, cardiac extracellular matrix remodeling, cardiomyocyte injury/death, oxidative stress, inflammation, neurohumoral activation, and renal dysfunction) [37]. In these regards, it is reasonable to expect the application of a multibiomarker approach for the improvement in management of HF and the personalization of care. From the results of our study, the presence of diabetes mellitus and anemia, but not B-type natriuretic peptide, was associated with elevated levels of PDW. This suggested that the underlying mechanisms of high PDW were
different from left ventricular stretch or diastolic wall stress [38, 39]. Levels of PDW show a positive correlation with hemoglobin A1c [40]. Patients with diabetes mellitus, particularly those with microvascular complications, show increased levels of PDW [41]. Previous studies suggested that the prothrombotic state due to insulin resistance and insulin deficiency may have contributed to increasing platelet reactivity [41, 42]. Patients with diabetes mellitus demonstrate increased platelet activation and increased release of prothrombotic and proinflammatory agents due to systematic inflammation, oxidative stress, impaired calcium metabolism, decreased bioavailability of nitric oxide, increased phosphorylation and glycosylation of cellular proteins [43]. More active platelets have more prothrombic contents, such as thromboxane A2, thromboxane B2, platelet factor 4, serotonin, and platelet-derived growth factor [44].

Thus, HF patients with increased PDW are suspected to have these underlying pathophysologies. On the other hand, anemia is associated with myocardial remodeling, inflammation, and volume overload in patients with HF [45]. However, the link between anemia and PDW has been unclear. Levels of PDW depend on whether platelets are hypoproductive such as aplastic anemia or hyperdestructive [46]. The clinical implications of PDW in anemia should be investigated by further studies because the leading cause of anemia was not recorded in this study. Thus, PDW is useful for multifaceted assessment of the pathophysiology of HF.

An unexpected finding of our results was that patients in the 1st tertile showed several worse characteristics compared to those in the 2nd tertile. Levels of B-type natriuretic peptide were obviously U-shaped. We were not able to explain the differences between patients in the 1st and 2nd tertiles due to the study protocol. However, after adjustment for important prognostic factors, the 3rd PDW tertile showed the worst outcome among the tertiles. Although there have been various studies on the association between PDW and CAD, evidence for PDW on HF has been little. Further studies are needed to clarify the clinical significance of PDW in patients with HF.

Study limitations
Due to the relatively small number of patients of this present study, the accurate PDW cut-off level should be investigated in further studies with larger populations. The underlying mechanisms influencing the levels of PDW need more investigation. The analyzed PDW levels were measured within 1 week prior to discharge; changes in PDW through the clinical course were not considered. There were some patients receiving anticoagulants for reasons other than atrial fibrillation (e.g. post-operative state). However, the leading cause of anticoagulant therapy was not taken into consideration in this study.

Conclusions
High PDW is an independent predictor of adverse prognosis in patients with HF.

Supporting information
S1 Table. Logistic regression analysis for the 3rd tertile (n = 543/1,746). OR, odds ratio; CI confidence interval; CAD, coronary artery disease; CKD, chronic kidney disease; RAS, renin-angiotensin system; Log-BNP, log-transformed B-type natriuretic peptide. * Adjusted for age, sex, and factors which had P values of < 0.05 in the unadjusted model.

S1 Dataset.

(DoCX)

(SAV)
Acknowledgments
The authors thank Ms. Kumiko Watanabe, Ms. Hitomi Kobayashi, Ms. Yumi Yoshihisa, and Ms. Tomiko Miura for their technical assistance.

Author Contributions
Conceptualization: Yu Sato, Akiomi Yoshihisa, Koichiro Watanabe, Yu Hotsuki, Yusuke Kimishima, Tetsuro Yokokawa, Tomofumi Misaka, Takamasu Sato, Takashi Kaneshiro, Masayoshi Oikawa, Atsushi Kobayashi, Yasuchika Takeishi.

Data curation: Yu Sato, Akiomi Yoshihisa.

Formal analysis: Yu Sato, Akiomi Yoshihisa, Koichiro Watanabe, Yu Hotsuki, Yusuke Kimishima, Tetsuro Yokokawa, Tomofumi Misaka, Takamasu Sato, Takashi Kaneshiro, Masayoshi Oikawa, Atsushi Kobayashi, Yasuchika Takeishi.

Funding acquisition: Akiomi Yoshihisa.

Investigation: Yu Sato, Akiomi Yoshihisa, Koichiro Watanabe, Yu Hotsuki, Yusuke Kimishima, Tetsuro Yokokawa, Tomofumi Misaka, Takamasu Sato, Takashi Kaneshiro, Masayoshi Oikawa, Atsushi Kobayashi, Yasuchika Takeishi.

Methodology: Yu Sato, Akiomi Yoshihisa, Koichiro Watanabe, Yu Hotsuki, Yusuke Kimishima, Tetsuro Yokokawa, Tomofumi Misaka, Takamasu Sato, Takashi Kaneshiro, Masayoshi Oikawa, Atsushi Kobayashi, Yasuchika Takeishi.

Project administration: Akiomi Yoshihisa, Yasuchika Takeishi.

Resources: Akiomi Yoshihisa.

Supervision: Akiomi Yoshihisa, Yasuchika Takeishi.

Visualization: Yu Sato, Akiomi Yoshihisa.

Writing – original draft: Yu Sato, Akiomi Yoshihisa, Yasuchika Takeishi.

Writing – review & editing: Koichiro Watanabe, Yu Hotsuki, Yusuke Kimishima, Tetsuro Yokokawa, Tomofumi Misaka, Takamasu Sato, Takashi Kaneshiro, Masayoshi Oikawa, Atsushi Kobayashi.

References
1. Ponikowski P, Voors AA, Anker SD, Bueno H, Crieland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016; 37 (27):2129–200. https://doi.org/10.1093/eurheartj/ehw128 PMID: 27206819.

2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/Ameri- can Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16):e147–239. https://doi.org/10.1016/j.jacc.2013 .05.019 PMID: 23747642.

3. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. Journal of the American College of Cardiology. 2001; 38(4):955–62. https://doi.org/10.1016/s0735-1097(01)01470-x PMID: 11583864

4. Felker GM, Allen LA, Pocock SJ, Shaw LK, McMurray JJ, Pfeffer MA, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARMM Program and the Duke Databank. J Am Coll Cardiol. 2007; 50(1):40–7. https://doi.org/10.1016/j.jacc.2007.02.067 PMID: 17601544.
5. Tonelli M, Sacks F, Arnold M, Moye L, Davis B, Pfeffer M, et al. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease. Circulation. 2008; 117 (2):163–8. https://doi.org/10.1161/CIRCULATIONAHA.107.727545 PMID: 18172029.

6. Ren X, Meng Z, Liu M, Zhu M, He Q, Zhang Q, et al. No associations exist between mean platelet volume or platelet distribution width and thyroid function in Chinese. Medicine (Baltimore). 2016; 95(40): e4573. https://doi.org/10.1097/MD.0000000000004573 PMID: 27749526; PubMed Central PMCID: PMCP5059028.

7. Rechcinski T, Jasinska A, Forys J, Krzeminska-Pakula M, Wierzbowska-Drabik K, Plewka M, et al. Prognostic value of platelet indices after acute myocardial infarction treated with primary percutaneous coronary intervention. Cardio J. 2013; 20(5):491–8. https://doi.org/10.5603/CJ.2013.0134 PMID: 24469872.

8. Vatankulu MA, Sonmez O, Ertas G, Bacaksz A, Turfan M, Erdogan E, et al. A new parameter predicting chronic total occlusion of coronary arteries: platelet distribution width. Angiology. 2014; 65(1):60–4. https://doi.org/10.1177/1075109713486339 PMID: 23636855.

9. Li B, Lu J, Peng DZ, Zhang XY, You Z. Elevated platelet distribution width predicts poor prognosis in hilar cholangiocarcinoma. Medicine (Baltimore). 2020; 99(12):e19400. https://doi.org/10.1097/MD.0000000000019400 PMID: 32195935.

10. Soydinc S, Turkbeyler IH, Pehlivyan V, Soylu G, Goktepe MF, Bilici M, et al. Mean platelet volume seems to be a valuable marker in patients with systemic sclerosis. Inflammation. 2014; 37(1):100–6. https://doi.org/10.1016/j.inflammas.2013.10.009 PMID: 23996103.

11. Chandra shekar L, Rajappa M, Revathy G, Sundar I, Munisamy M, Ananthanarayan PH, et al. Is enhanced platelet activation the missing link leading to increased cardiovascular risk in psoriasis? Clin Chim Acta. 2015; 446; 181–5. https://doi.org/10.1016/j.cca.2015.04.023 PMID: 25920693.

12. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323(4):236–41. https://doi.org/10.1056/NEJM199007263230405 PMID: 2195340.

13. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995; 92(6):1479–86. https://doi.org/10.1161/01.cir.92.6.1479 PMID: 7664430.

14. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Onishi M, Fukai D, et al. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol. 1998; 31(2):391–8. https://doi.org/10.1016/s0735-1097(97)00494-4 PMID: 9462584.

15. Isik T, Ayhan E, Uyarel H, Ergelen M, Tanboga IH, Kurt M, et al. Increased mean platelet volume associated with extent of slow coronary flow. Cardiol J. 2012; 19(4):355–62. https://doi.org/10.5603/cj.2012.0065 PMID: 22825985.

16. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure- Digest Version. Circ J. 2019; 83(10):2084–184. Epub 2019/09/13. https://doi.org/10.1253/circj.CJ-19-0342 PMID: 31511430.

17. Yoshihisa A, Ichijo Y, Watanabe K, Sato Y, Kanno Y, Takiguchi M, et al. Prior History and Incidence of Cancer Impacts on Cardiac Prognosis in Hospitalized Patients With Heart Failure. Circ J. 2019; 83(8):1708–17. https://doi.org/10.1253/circj.CJ-19-0279 PMID: 31243245.

18. Yoshihisa A, Sato Y, Kanno Y, Takiguchi M, Yokokawa T, Abe S, et al. Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction. Circ J. 2020; 84(2):e001112. https://doi.org/10.1136/circj-2019-001112 PMID: 32341787; PubMed Central PMCID: PMC7174028.

19. Beutler E, Waalen J. The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration? Blood. 2006; 107(5):1747–50. https://doi.org/10.1182/blood-2005-07-3046 PMID: 16189263; PubMed Central PMCID: PMCP1895695.

20. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67(6):2089–100. https://doi.org/10.1111/j.1523-1755.2005.00365.x PMID: 15882252.

21. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6):982–92. https://doi.org/10.1053/ajkd.2008.12.034 PMID: 19339088.

22. Rickham PP. Human Experimentation. Code of Ethics of the World Medical Association. Declaration of Helsinki. Br Med J. 1964; 2(5402):177. https://doi.org/10.1136/bmj.2.5402.177 PMID: 14150888; PubMed Central PMCID: PMC1816102.
Association between PDW and prognosis in patients with HF

23. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007; 335(7624):806–8. https://doi.org/10.1136/bmj.39335.541782.AD PMID: 17947786; PubMed Central PMCID: PMC2034723.

24. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013; 48(3):452–8. https://doi.org/10.1038/bmt.2012.244 PMID: 23208313; PubMed Central PMCID: PMC3590441.

25. Larsen SB, Grove EL, Hvas AM, Kristen sen SD. Platelet turnover in stable coronary artery disease— influence of thrombopoietin and low-grade inflammation. PLoS One. 2014; 9(1):e85566. https://doi.org/10.1371/journal.pone.0085566 PMID: 24465602; PubMed Central PMCID: PMC3897460.

26. Hu CP, Du Y, Zhu Y, Shi C, Qin Z, Zhao YX. Platelet Distribution Width on Admission Predicts In-Stent Restenosis in Patients with Coronary Artery Disease and Type 2 Diabetes Mellitus Treated with Percutaneous Coronary Intervention. Chin Med J (Engl). 2018; 131(7):757–63. https://doi.org/10.4103/0366-6999.228247 PMID: 29578117; PubMed Central PMCID: PMC5887732.

27. Vagdatli E, Gounari E, Lazaridou E, Katsibourlia E, Tsikopoulos F, Labrianou I. Platelet distribution width: a simple, practical and specific marker of activation of coagulation. Hippokratia. 2010; 14(1):28–32. PMID: 20411056; PubMed Central PMCID: PMC2843567.

28. Kayacan O, Narkal D, Beder S, Gullu E, Tutkak H, Senler FC, et al. Impact of TNF-alpha and IL-6 levels on development of cachexia in newly diagnosed NSCLC patients. Am J Clin Oncol. 2006; 29(4):328–33. https://doi.org/10.1097/01.coc.000021300.72657.e0 PMID: 16891858.

29. Sincer I, Mansiroglu AK, Erdal E, Cosgun M, Aktas G, Gunes Y. Could platelet distribution width be used as a parameter in predicting coronary collateral development in stable coronary artery disease? North Clin Istanbul. 2020; 7(2):112–7. https://doi.org/10.14744/nci.2019.47374 PMID: 32259031; PubMed Central PMCID: PMC7117641.

30. Thompson CB, Eaton KA, Princiotta SM, Rushin CA, Valeri CR. Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol. 1982; 50(3):509–19. https://doi.org/10.1111/j.1365-2458.1982.tb01947.x PMID: 7066203.

31. Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009; 102(2):248–57. https://doi.org/10.1160/TH09-03-0192 PMID: 19652875.

32. Akin F, Ayca B, Kose N, Altun I, Avsar M, Celik O, et al. Relation of platelet indices to severity of coronary artery disease in patients undergoing primary percutaneous coronary intervention. Perfusion. 2016; 31(3):216–22. https://doi.org/10.1177/0267659115594231 PMID: 26178072.

33. De Luca G, Venegoni L, Iorio S, Secco GG, Cassetti E, Verdoia M, et al. Platelet distribution width and the extent of coronary artery disease: results from a large prospective study. Platelets. 2010; 21(7):508–14. https://doi.org/10.3109/09537104.2010.494743 PMID: 20874431.

34. Ulucan S, Keser A, Kaya Z, Katlandur H, Ozdil H, Bilgi M, et al. Association between PDW and Long Term Major Adverse Cardiac Events in Patients with Acute Coronary Syndrome. Heart Lung Circ. 2016; 25(1):29–34. https://doi.org/10.1016/j.hlc.2015.05.017 PMID: 26168154.

35. Bekker A, Ozkam MT, Tenekcioglu E, Gazi E, Yener AU, Temiz A, et al. Increased Platelet Distribution Width Is Associated With Severity of Coronary Artery Disease in Patients With Acute Coronary Syndrome. Angiology. 2015; 66(7):638–43. https://doi.org/10.1177/0003319714545779 PMID: 25112777.

36. He S, Lei W, Li J, Yu K, Yu Y, Zhou L, et al. Relation of Platelet Parameters With Incident Cardiovascular Disease (The Dongfeng-Tongji Cohort Study). Am J Cardiol. 2019; 123(2):239–48. https://doi.org/10.1016/j.amjcard.2018.10.016 PMID: 30412427.

37. Ibrahim NE, Januzzi JL Jr. Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. Clin Chem. 2017; 63(1):211–22. Epub 2017/01/08. https://doi.org/10.1373/clinchem.2016.259564 PMID: 28062619.

38. Tokola H, Hautala N, Marttila M, Magga J, Pikkarainen S, Kerkela R, et al. Mechanical load-induced alterations in B-type natriuretic peptide gene expression. Can J Physiol Pharmacol. 2001; 79(8):646–53. PMID: 11558673.

39. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006; 47(4):742–8. https://doi.org/10.1016/j.jacc.2005.11.030 PMID: 16487838.

40. Demirtas L, Degermenci H, Akbas EM, Ozcicek A, Timuroglu A, Gurel A, et al. Association of hematological indices with diabetes, impaired glucose regulation and microvascular complications of diabetes. Int J Clin Exp Med. 2015; 8(7):11420–7. PMID: 26379956; PubMed Central PMCID: PMC4565341.

41. Jindal S, Gupta S, Gupta R, Kakkar A, Singh HV, Gupta K, et al. Platelet indices in diabetes mellitus: indicators of diabetic microvascular complications. Hematology. 2011; 16(2):86–9. https://doi.org/10.1179/102453311X12902908412110 PMID: 21418738.
42. Liu J, Liu X, Li Y, Quan J, Wei S, An S, et al. The association of neutrophil to lymphocyte ratio, mean platelet volume, and platelet distribution width with diabetic retinopathy and nephropathy: a meta-analysis. Biosci Rep. 2018; 38(3). https://doi.org/10.1042/BSR20180172 PMID: 29581246; PubMed Central PMCID: PMC6019380.

43. El Haouari M, Rosado JA. Platelet signalling abnormalities in patients with type 2 diabetes mellitus: a review. Blood Cells Mol Dis. 2008; 41(1):119–23. https://doi.org/10.1016/j.bcmd.2008.02.010 PMID: 18387322.

44. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? Curr Pharm Des. 2011; 17(1):47–58. https://doi.org/10.2174/138161211795049804 PMID: 21247392.

45. O’Meara E, Rouleau JL, White M, Roy K, Blondeau L, Ducharme A, et al. Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes. Circ Heart Fail. 2014; 7(5):773–81. https://doi.org/10.1161/CIRCHEARTFAILURE.114.001100 PMID: 25027873.

46. Jeon K, Kim M, Lee J, Lee JS, Kim HS, Kang HJ, et al. Immature platelet fraction: A useful marker for identifying the cause of thrombocytopenia and predicting platelet recovery. Medicine (Baltimore). 2020; 99(7):e19096. https://doi.org/10.1097/MD.00000000000019096 PMID: 32049816; PubMed Central PMCID: PMC7035018.